Health ProductsDear Healthcare Professional Letter

Type II Product Recall of Apo-Lithium Carbonate SR 300 mg strength tablets - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Apotex Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Apo-Lithium Carbonate SR 300 mg strength tablets

26 October 2009

Dear Health Care Professional,

Subject: Type II Product Recall of Apo-Lithium Carbonate SR 300 mg strength tablets.

Product Strength DIN Package Type Lot/Batch Nos. Expiry date
Apo-Lithium
Carbonate
SR
300 mg 02266695 Bottles of 100 tablets HT 9748 2010/03
HV 7090 2010/05
HX 9290 2010/07

Apotex Inc., in collaboration with Health Canada, wishes to advise health care professionals that a recall of Apo-Lithium Carbonate SR 300 mg strength tablets was initiated on 20 October 2009 due to stability issues which may have had an impact on the quality of the product. Given the recall, a shortage of sustained release preparation of lithium may occur in which case patients taking Apo-Lithium Carbonate SR 300 mg may need to be switched to an alternate lithium preparation. Alternate lithium options include other sustained release preparations or immediate release preparations. In the event that a patient is switched to an immediate release formulation of lithium carbonate, titration of dose, careful monitoring of lithium blood levels, adverse effects and compliance is advised.

Apo-Lithium Carbonate is indicated in the lithium treatment of manic episodes of manic-depressive illness. Maintenance therapy has been found to be useful in preventing or diminishing the frequency of subsequent relapses in bipolar manic-depressive patients (with a history of mania).Footnote 1

  • Pharmacists are requested to refer patients to their physicians immediately for alternate therapy if they are unable to fill a patient's prescription with Lithium Carbonate SR 300 mg.
  • Physicians are requested to be accessible to their patients who may need to be switched from the sustained release product to an immediate release version.
  • In light of the narrow therapeutic index when using lithium, physicians are reminded to titrate lithium doses carefully and to monitor lithium blood levels closely, if and when a change is made to immediate release lithium formulations.

Managing marketed health product-related adverse reactions depend on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. We encourage the reporting of adverse effects to either Apotex Inc. or Health Canada at the following addresses:

Apotex Inc.
150 Signet Drive
Toronto, ON
M9L 1T9
Telephone: 1-800-667-4708
Fax: 416-401-3819
E-mail: drugsafety@apotex.com

Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 866-234-2345
Fax: 866-678-6789
CanadaVigilance@hc-sc.gc.ca

The Adverse Reaction Reporting Form and the Adverse Reaction Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Health Product and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 613-946-5636

Sincerely,

original signed by

Lance Lovelock
Vice President Quality Assurance

original signed by

Colin D'Cunha MBBS,MHSc,FRCPC
Director - Global Pharmacovigilance

References:

References:

Footnote 1

Canadian Product Monograph, Apo-Lithium Carbonate SR, 300 mg. Revised November 22, 2005; page 5

Return to footnote 1 referrer

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime